hotspot -WSS

hotspot

author：Wikipedia 2025-10-02 13:01:26 - browse：2

The Novartis booth at ESMO in Madrid. — The Novartis booth at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic prostate cancer, moving it from a treatment used after chemotherapy to one with demonstrated benefits beforehand as well.

The Phase 3 data, highlighted in a prime session here at the annual meeting of the European Society for Medical Oncology, also amount to another win for cancer therapies designed to deliver radiation directly to tumor cells. It’s a field that Novartis has poured investments into, and that is attracting interest from other pharma companies.

The trial, called PSMAfore, enrolled patients with a type of metastatic prostate cancer whose disease had started to progress after taking a drug known as an androgen receptor pathway inhibitor, or ARPI. Patients were randomized to either receive a different ARPI or Novartis’ therapy, Pluvicto.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Today's health inequities arise from racist U.S. history, say experts

entertainment

WSS

Search resumes for 2 missing children washed away with mom in deadly Pennsylvania flash flood

A look at other Americans who have crossed into North Korea over the years

Study suggests Covid rebound is far more common with Paxlovid than without

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Ventyx halts psoriasis drug development after lackluster trial results

BridgeBio heart drug succeeds in pivotal study

explore

hotspot

knowledge

In Memoriam: Notable people who died in 2023

NIH chief: government has fallen behind pharma on clinical trials

Walensky prepares to leave CDC — and Congress — behind

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Medicare details structure of new drug price negotiation program

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Trump demands the U.S. pay no more for drugs than other countries … again

Lack of darker skin in textbooks, journals harms patients of color

Medical leaders decry Supreme Court decision on affirmative action

Readout Newsletter: Zepbound, Valneva's vaccine, and more

focus

After decades in use, heart stents finally beat placebo

Readout Newsletter: Ozempic panic wanes, Legend x Novartis, etc.

What is STAT's opinion section for?

A letter from the executive editor: STAT UnitedHealth investigation

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

More hospitals are billing patients as online messages surge

focus

leisure time

entertainment

knowledge